Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026

Anixa advances its ovarian cancer CAR-T trial with no dose-limiting toxicities so far.

What the company is saying

Anixa Biosciences is highlighting progress in its Phase 1 clinical trial of liraltagene autoleucel (lira-cel), a CAR-T therapy targeting the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer. The company emphasizes the completion of the fifth dosing cohort, where patients received 1x10⁷ CAR-positive cells/kg, a 100-fold increase over the initial dose, and plans to escalate to a sixth cohort at 1x10⁸ CAR-positive cells/kg, a 1,000-fold increase. The announcement stresses the absence of dose-limiting toxicities to date and reports preliminary clinical signals: one patient with stable disease at 90 days post-treatment and four patients surviving more than a year, including one over two years. Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center and principal investigator, will present these findings at the ESMO Immuno-Oncology & Advanced Therapies Congress on December 14, 2026. The company frames its CER-T technology as differentiated by targeting FSHR with the natural ligand FSH rather than an antibody fragment. Anixa also references a broader oncology pipeline, including vaccine collaborations with Cleveland Clinic, but provides no new data on these programs. The tone is optimistic, focusing on clinical milestones and scientific recognition.

What the data suggests

The Phase 1 trial (NCT05316129) has completed five dose-escalation cohorts, with the latest group receiving 1x10⁷ CAR-positive cells/kg, and plans to escalate to 1x10⁸ CAR-positive cells/kg, marking a 1,000-fold increase from the initial 1x10⁵ CAR-positive cells/kg dose. No dose-limiting toxicities have been observed, supporting the safety profile at escalating doses. Preliminary efficacy signals are limited: one patient showed stable disease 90 days post-treatment, and four patients have survived more than a year, including one beyond two years. These outcomes are encouraging for a Phase 1 trial but do not establish efficacy. The company discloses no financial figures, revenue, or cash data. The announcement is transparent about clinical progress and dosing but does not provide objective response rates, progression-free survival, or comparative benchmarks. The broader vaccine pipeline is mentioned without quantitative or stage-specific details. The evidence supports ongoing safety and some potential for clinical benefit, but the data set is too small for robust conclusions.

Analysis

The announcement provides a detailed update on Anixa's ongoing Phase 1 clinical trial, including specific dosing regimens, safety observations, and preliminary patient outcomes. The tone is positive, emphasizing the absence of dose-limiting toxicities and some encouraging survival data. However, the majority of the claims are factual and relate to realised milestones (e.g., completion of the fifth cohort, observed patient outcomes), with only a small portion being forward-looking (anticipated sixth cohort, future presentations). The broader statements about the company's vaccine portfolio and business model are promotional but lack supporting data or specifics about progress or commercial potential. No financial or profitability metrics are disclosed, which is typical for an early-stage biotech but limits the ability to assess value creation. The hype is moderate, mainly due to the inclusion of aspirational language about the pipeline and partnerships without concrete evidence of near-term impact.

Risk flags

• ●Clinical development risk remains high, as the trial is only in Phase 1 and efficacy signals are preliminary and based on a small patient cohort. Early safety is promising, but larger studies are needed to confirm benefit and rule out rare adverse events.
• ●The absence of financial disclosure, including cash position and R&D spend, leaves investors unable to assess the company’s runway or funding needs, which is material for an early-stage biotech advancing dose-escalation trials.
• ●The announcement references a broader pipeline and vaccine collaborations, but provides no stage, data, or timelines for these programs, making it difficult to gauge their potential contribution or risk of dilution of focus and resources.

Bottom line

Anixa’s update confirms steady progress in its Phase 1 ovarian cancer CAR-T trial, with no dose-limiting toxicities observed through five escalating cohorts and plans to move to a 1,000-fold higher dose. Early clinical signals—such as stable disease in one patient and multi-year survival in four—are encouraging but not yet sufficient to establish efficacy. The involvement of Dr. Robert Wenham and the upcoming ESMO presentation lend scientific credibility but do not guarantee future success or regulatory advancement. The lack of financial data and limited efficacy results mean investors have little basis for assessing near-term value or risk. The most actionable takeaway is that safety at higher doses is holding, with the next inflection point being data from the sixth cohort and any subsequent efficacy disclosures. Investors should watch for more granular clinical outcomes and financial transparency in future updates.

Announcement summary

(NASDAQ:ANIX) Anixa Biosciences, Inc. announced that Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center and principal investigator of Anixa's ongoing Phase 1 clinical trial, will present at the ESMO Immuno-Oncology & Advanced Therapies Congress 2026 in London on December 14, 2026. The presentation is titled "Phase 1 clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer." Anixa's Phase 1, dose-escalating clinical trial (ClinicalTrials.gov NCT05316129) is being conducted at Moffitt Cancer Center and is evaluating the safety, tolerability, and preliminary efficacy of liraltagene autoleucel (lira-cel), a novel CAR-T therapy targeting FSHR. The company recently completed treatment of the fifth cohort in the trial, in which patients received 1x10⁷ CAR-positive cells per kilogram of body weight following lymphodepletion, representing a 100-fold increase over the dose administered to the first patient. Following routine safety verification, Anixa anticipates advancing to a sixth cohort at a dose of 1x10⁸ CAR-positive cells/kg, representing a 1,000-fold increase over the initial dose of 1x10⁵ CAR-positive cells/kg. To date, no dose-limiting toxicities have been observed in the study. Preliminary clinical observations include the first patient exhibiting stable disease 90 days after treatment and four patients surviving more than one year after treatment, including one patient who has survived beyond two years. Lira-cel uses chimeric endocrine receptor-T cell (CER-T) technology, which is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Anixa's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines targeting high incidence malignancies in lung, colon, and prostate. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa, with Cleveland Clinic entitled to royalties and other commercialization revenues from these vaccine technologies. Anixa's business model involves partnering with world-renowned research institutions at all stages of development to examine emerging technologies for further development and commercialization.

Disagree with this article?